A Randomized, Double-blinded, Phase 3, Multicenter, Investigator-initiated Trial for Entecavir for Prophylaxis of Hepatitis B Virus (HBV) Reactivation in HBV Surface Antigen or Anti-HBc Positive Patients Undergoing Anti-TNFalpha Treatment
Phase of Trial: Phase III
Latest Information Update: 18 Sep 2019
Price : $35 *
At a glance
- Drugs Entecavir (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- 02 Mar 2017 Status changed from recruiting to discontinued.
- 19 Oct 2012 New source identified and integrated (Clinical Research Information Service (CriS) - Republic of Korea, KCT0000554).
- 05 Oct 2012 New trial record